Zobrazeno 1 - 4
of 4
pro vyhledávání: '"David Hosfield"'
Autor:
Emre Sevgen, Joshua Moller, Adrian Lange, John Parker, Sean Quigley, Jeff Mayer, Poonam Srivastava, Sitaram Gayatri, David Hosfield, Maria Korshunova, Micha Livne, Michelle Gill, Rama Ranganathan, Anthony B. Costa, Andrew L. Ferguson
The data-driven design of protein sequences with desired function is challenged by the absence of good theoretical models for the sequence-function mapping and the vast size of protein sequence space. Deep generative models have demonstrated success
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64c920f3acf3e7849a02e4f8b84b588e
https://doi.org/10.1101/2023.01.23.525232
https://doi.org/10.1101/2023.01.23.525232
Autor:
Sean Fanning, Govinda Hancock, Kristen Young, David Hosfield, Carstyn Joiner, Emily Sullivan, Yoldas Yildiz, Muriel Laine, Geoffrey Greene
Estrogen receptor alpha (ERα) is a ligand-dependent master transcriptional regulator and key driver of breast cancer pathology. Small molecule hormones and competitive antagonists favor unique ERα conformational ensembles that elicit ligand-specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e27d311eb4c78f8a505f5ad8a5879ea
https://doi.org/10.21203/rs.3.rs-1923089/v1
https://doi.org/10.21203/rs.3.rs-1923089/v1
Publikováno v:
Cancer Research. 83:3439-3439
Breast and prostate cancer are the leading cancer diagnoses for women and men, respectively, second only to cutaneous cancers. Breast and prostate cancer arise from aberrant estrogen/estrogen receptor (ER) and testosterone/androgen receptor signaling
Autor:
Muriel Laine, Sylvie Madar, Sandra Weber, David Hosfield, Madaline Sauvage, Nan-Sheng Li, Geoffrey L. Greene, Ross Han, Sean W. Fanning
Publikováno v:
Cancer Research. 81:2472-2472
Approximately 50% of luminal breast cancer patients become resistant to first-line endocrine therapies after an average of 5 years. Acquired activating mutations to the ESR1 ligand binding domain enable hormone therapy resistance in approximately 25-